<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d561">
    <sentence id="DDI-DrugBank.d561.s0" text="Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.">
        <entity id="DDI-DrugBank.d561.s0.e0" charOffset="0-8"
            type="group" text="Diuretics"/>
        <entity id="DDI-DrugBank.d561.s0.e1" charOffset="23-31"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d561.s0.e2" charOffset="203-210"
            type="brand" text="Lotensin"/>
        <ddi id="DDI-DrugBank.d561.s0.d0" e1="DDI-DrugBank.d561.s0.e1"
            e2="DDI-DrugBank.d561.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s1" text="The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.">
        <entity id="DDI-DrugBank.d561.s1.e0" charOffset="44-51"
            type="brand" text="Lotensin"/>
        <entity id="DDI-DrugBank.d561.s1.e1" charOffset="98-105"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d561.s1.e2" charOffset="175-182"
            type="brand" text="Lotensin"/>
        <ddi id="DDI-DrugBank.d561.s1.d0" e1="DDI-DrugBank.d561.s1.e1"
            e2="DDI-DrugBank.d561.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s2" text="If this is not possible, the starting dose should be reduced."/>
    <sentence id="DDI-DrugBank.d561.s3" text="Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.">
        <entity id="DDI-DrugBank.d561.s3.e0" charOffset="0-8"
            type="drug" text="Potassium"/>
        <entity id="DDI-DrugBank.d561.s3.e1" charOffset="26-52"
            type="group" text="Potassium-Sparing Diuretics"/>
        <entity id="DDI-DrugBank.d561.s3.e2" charOffset="102-119"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d561.s3.d0" e1="DDI-DrugBank.d561.s3.e1"
            e2="DDI-DrugBank.d561.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s4" text="Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.">
        <entity id="DDI-DrugBank.d561.s4.e0" charOffset="0-26"
            type="group" text="Potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d561.s4.e1" charOffset="29-42"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d561.s4.e2" charOffset="45-53"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d561.s4.e3" charOffset="56-66"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d561.s4.e4" charOffset="84-92"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s5" text="Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patient's serum potassium should be monitored frequently."/>
    <sentence id="DDI-DrugBank.d561.s6" text="Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.">
        <entity id="DDI-DrugBank.d561.s6.e0" charOffset="5-18"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d561.s6.e1" charOffset="45-52"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d561.s6.e2" charOffset="58-70"
            type="drug" text="acenocoumarol"/>
        <entity id="DDI-DrugBank.d561.s6.e3" charOffset="181-194"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s7" text="Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.">
        <entity id="DDI-DrugBank.d561.s7.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d561.s7.e1" charOffset="25-31"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d561.s7.e2" charOffset="56-62"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d561.s7.e3" charOffset="114-127"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d561.s7.e4" charOffset="149-155"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d561.s7.d0" e1="DDI-DrugBank.d561.s7.e3"
            e2="DDI-DrugBank.d561.s7.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s8" text="These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.">
        <entity id="DDI-DrugBank.d561.s8.e0" charOffset="84-90"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s9" text="If a diuretic is also used, the risk of lithium toxicity may be increased.">
        <entity id="DDI-DrugBank.d561.s9.e0" charOffset="5-12"
            type="group" text="diuretic"/>
        <entity id="DDI-DrugBank.d561.s9.e1" charOffset="40-46"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d561.s9.d0" e1="DDI-DrugBank.d561.s9.e0"
            e2="DDI-DrugBank.d561.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s10" text="Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine.">
        <entity id="DDI-DrugBank.d561.s10.e0" charOffset="73-80"
            type="brand" text="Lotensin"/>
        <entity id="DDI-DrugBank.d561.s10.e1" charOffset="118-136"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d561.s10.e2" charOffset="139-152"
            type="drug" text="chlorthalidone"/>
        <entity id="DDI-DrugBank.d561.s10.e3" charOffset="155-164"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d561.s10.e4" charOffset="167-173"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d561.s10.e5" charOffset="176-186"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d561.s10.e6" charOffset="189-196"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d561.s10.e7" charOffset="199-206"
            type="drug" text="naproxen"/>
        <entity id="DDI-DrugBank.d561.s10.e8" charOffset="212-221"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s11" text="Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.">
        <entity id="DDI-DrugBank.d561.s11.e0" charOffset="0-7"
            type="brand" text="Lotensin"/>
        <entity id="DDI-DrugBank.d561.s11.e1" charOffset="42-72"
            type="group" text="beta-adrenergic-blocking agents"/>
        <entity id="DDI-DrugBank.d561.s11.e2" charOffset="75-105"
            type="group" text="calcium-channel-blocking agents"/>
        <entity id="DDI-DrugBank.d561.s11.e3" charOffset="108-116"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d561.s11.e4" charOffset="119-125"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d561.s11.e5" charOffset="132-142"
            type="drug" text="hydralazine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s12" text="Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system">
        <entity id="DDI-DrugBank.d561.s12.e0" charOffset="0-9"
            type="drug" text="Benazepril"/>
        <entity id="DDI-DrugBank.d561.s12.e1" charOffset="23-36"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d561.s12.e2" charOffset="79-102"
            type="group" text="beta-adrenergic blockers"/>
        <ddi id="DDI-DrugBank.d561.s12.d0" e1="DDI-DrugBank.d561.s12.e0"
            e2="DDI-DrugBank.d561.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d561.s12.d1" e1="DDI-DrugBank.d561.s12.e1"
            e2="DDI-DrugBank.d561.s12.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d561.s13" text="."/>
    <sentence id="DDI-DrugBank.d561.s14" text=""/>
</document>
